http://purl.org/np/RAB0lKFThg... RAB0lKFThg

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-13T11:19:45.930Z

http://purl.org/np/RAB0lKFThg... RAB0lKFThg

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

prochlorperazine maleate tablets are indicated for the control of severe nausea and vomiting prochlorperazine maleate tablets are also indicated for the treatment of schizophrenia prochlorperazine is effective for the short term treatment of generalized non psychotic anxiety however prochlorperazine maleate tablets are not the first drug to be used in therapy for most patients with non psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments e g benzodiazepines when used in the treatment of non psychotic anxiety prochlorperazine maleate tablets should not be administered at doses of more than 2 mg per day or for longer than 12 weeks because the use of prochlorperazine maleate tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible see warnings the effectiveness of prochlorperazine as treatment for non psychotic anxiety was established in 4 week clinical studies of outpatients with generalized anxiety disorder this evidence does not predict that prochlorperazine maleate tablets will be useful in patients with other non psychotic conditions in which anxiety or signs that mimic anxiety are found e g physical illness organic mental conditions agitated depression character pathologies etc prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation

Leoni Bücken

2021-06-13T11:19:45.930Z

http://purl.org/np/RAB0lKFThg... RAB0lKFThg

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_5419 DOID_5419

Leoni Bücken

2021-06-13T11:19:45.930Z

http://purl.org/np/RAB0lKFThg... RAB0lKFThg

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-13T11:19:45.930Z

http://purl.org/np/RAB0lKFThg... RAB0lKFThg

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00433 drugbank:DB00433

Leoni Bücken

2021-06-13T11:19:45.930Z

http://purl.org/np/RAB0lKFThg... RAB0lKFThg

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-13T11:19:45.930Z

http://purl.org/np/RAB0lKFThg... RAB0lKFThg

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-13T11:19:45.930Z

http://purl.org/np/RAB0lKFThg... RAB0lKFThg

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/TreatmentIndication TreatmentIndication

Leoni Bücken

2021-06-13T11:19:45.930Z